About Us 2 | Dupage Medical Technology, Inc.

About Us

Dupage Medical Technology, Inc. (DMT), a research and biotechnology company, is located in an Industrial park affiliated with the University of Illinois at Chicago. The major focus of our company is to develop effective and safer drugs to treat cardiovascular diseases that involve thrombosis and inflammation. Drugs currently under development include MB2mP6 and M3mP6 that are innovative peptide drugs encapsulated in a unique lipid formulation to yield high loading peptide nanoparticles (HLPN). These HLPN allow efficient intracellular peptide delivery enabling in vivo therapeutic use of peptides targeting the intracellular compartment. MB2mP6 and M3mP6 have both anti-inflammatory and anti-thrombotic effects by targeting a newly described signaling pathway in platelets and leukocytes. Despite potent anti-thrombotic effects, these drugs do not cause bleeding. The initial targeted indications are for the treatment of sepsis, myocardial ischemia/reperfusion injury (MI/RI) or renal ischemia/reperfusion injury (IRI). We have completed successful proof-of-concept animal studies showing the effectiveness of the drugs for these indications. These drugs also have the potential to be effective in treating other thrombo-inflammatory diseases such as acute respiratory distress syndrome (ARDS), stroke, bacterial pneumonia, etc.

Additionally, we have the unique patent-pending technology for generating HLPN, which is likely to attract customers with interests in developing peptide-based drugs to license this technology.

New drug development in the company has been supported by contracts/grants from the National Heart, Lung and Blood Institute. With the significant progress made in preclinical pharmacology and toxicology testing, we plan to raise an additional $10 million in private investment to support additional preclinical pharmacology and toxicology studies for IND approval and phase I clinical trials.

The Team

Xiaoping Du, MD, PhD

Xiaoping Du received medical degree from Suzhou Medical College, China, and PhD degree from the University of Sydney, Australia. He is UIC Distinguished…

Email Me

Aleksandra Stojanovic, MS

Aleksandra is Chief Operating Officer at DuPage Medical Technology (DMT). She joined the company in 2020. With her entrepreneurial…

Email Me

Randal A. Skidgel, PhD

Randal joined DuPage Medical Technology (DMT) as Senior Scientific Officer in 2016. He brings to DMT extensive experience in research on peptide…

Email Me

Yong-Jian Geng, MD, PhD

Dr. Yong-Jian Geng received his medical degree in 1982 from Suzhou Medical College, China, and doctoral degree of medical science in clinic…

Email Me

Invest In Us

Call our team today to schedule a meeting.

Contact

Email Me

Xiaoping Du, MD

Xiaoping Du received medical degree from Suzhou Medical College, China, and PhD degree from the University of Sydney, Australia. He is UIC Distinguished Professor in the Department of Pharmacology and Regenerative Medicine, University of Illinois Chicago. He is an expert in studying thrombosis (“clotting”), bleeding and inflammation. His works are published in famous scientific journals including “Nature”, “Science”, “Cell” and “Science Translational Medicine”. He is also an inventor with numerous patents, some of which are licensed by Dupage Medical Technology, Inc. He served on the editorial board of Blood and is the current editorial board member of the journal Arterioslcerosis, Thrombosis and Vascular biology. He also served on numerous NIH review panels and received Special Recognition Award in Thrombosis from the ATVB Council of American Heart Association.

Email Me

Aleksandra Stojanovic, MS

Aleksandra is Chief Operating Officer at DuPage Medical Technology (DMT). She joined the company in 2020. With her entrepreneurial skills, she brings to DMT important experience in mapping and launching company to the next level of operation. Prior to DMT, Aleksandra was a Senior Research Specialist in the Department of Pharmacology at the University of Illinois College of Medicine at Chicago as a lab manager for 15 years. She is also a successful entrepreneur and NLP coach, specializing in performance and mindset.

Aleksandra earned MS in Biochemical Engineering and Biotechnology from College of Technology and Metallurgy, University of Belgrade, Serbia, with specialization in encapsulation and bioproduction.

As a part of her current position at DMT, Aleksandra is responsible for overseeing and managing the company's daily business operations. She also works closely with the research and development department on production of peptide nanoparticle drugs. She develops, implements, supports, and prepares companies in the process of scaling.

Email Me

Randal A. Skidgel, PhD

Randal joined DuPage Medical Technology (DMT) as Senior Scientific Officer in 2016. He brings to DMT extensive experience in research on peptide hormone signaling, vascular biology and endothelial barrier function and its dysregulation under inflammatory conditions. Prior to DMT, Randal was a professor in the Department of Pharmacology at the University of Illinois College of Medicine at Chicago for 31 years where, as a PI, successfully conducted NIH-funded research resulting in over 130 peer- reviewed publications.

Randal received a BA in Chemistry from Point Loma College and a PhD in Pharmacology and Physiology from the University of California, San Diego. He completed his postdoctoral training at the University of Texas Southwestern Medical School in the Department of Pharmacology. At DMT, Randal oversees the research and development of peptide nanoparticle drugs that block the interaction of Gα13 with β3 and β2 integrins to inhibit outside-in signaling in platelets and leukocytes to treat thrombo-inflammatory diseases such as sepsis and ischemia-reperfusion injury. So far, this work has led to the publication of 3 papers (in the Journal of Immunology, Nature Communications and Science Translational Medicine) and the funding of an SBIR Phase I grant and two SBIR Phase II grants.

Email Me

Yong-Jian Geng, MD, PhD

Dr. Yong-Jian Geng received his medical degree in 1982 from Suzhou Medical College, China, and doctoral degree of medical science in clinic chemistry in 1994 from Gothenburg University, Sweden. In 1989, he completed a fellowship in immunopathology, INSERM U291, France, and in 1989, a cardiology research fellowship at the Brigham and Women’s Hospital, Harvard Medical School (1994-1995). In 1995, He was appointed as Instructor of Medicine in Harvard Medical School, Assistant Professor of Medicine (tenure-track) at the Allegheny University of Health Sciences in Pittsburgh (1996-1999) and then University of Texas Houston Medical School (1999-2002), Associate Professor (2002-2005), and full Professor of Medicine, Nanomedicine, and Biomedical Engineering (2005-2022) at the University of Texas Houston Medical School. In 2000, he was named Director of Stem Cells and Heart Failure Research at Texas Heart Institute. Since 1999, Dr. Geng has served as a full faculty member of the University of Texas MD Anderson Cancer Center/UTHealth Graduate School for Biomedical Sciences, the courses of Vascular Biology and Stem Cells in Biomedicine. Dr. Geng is an internationally recognized cardiovascular researcher who has contributed in the field of atherosclerosis, vascular immunology, inflammation, apoptosis and stem cell therapy. His research is currently focused on the molecular and cellular mechanisms underlying the pathogenesis of atherosclerosis and heart failure, and at developing new therapeutic approaches to treat cardiovascular diseases with stem cells. Dr. Geng has received numerous awards and honors, including the Technology Transfer Awards (1989 and 1994) from the International Union Against Cancer (UICC), Geneva, the First Award from the National Institutes of Health (1997); ARA Award from Parke-Davis/Pfizer Foundation (2000); and the Fourjay Foundation Cardiovascular Research Award (2001). Dr. Geng is an internationally recognized expert in stem cell research, and is a member of numerous research review committees, including those of the American Heart Association and the National Institutes of Health. He served on the editorial boards of many scientific journals, such as Circulation and Circulation Research, two top journals of the American Heart Association. He is also members of editorial boards of other professional journals, such as Vascular Pharmacology, and World Journal of Stem Cells. He served as a keynote or invited speaker and presenter in many professional conferences and different universities worldwide. As a very productive physician-scientist Dr. Geng has published many scientific articles, book chapters and reviews. Thus far, his Google Scholar profile has had 16306 citations and h-index 62. Dr. Geng is a founder of several biotech startups and inventor of more than 20 US and international patents, awarded or pending. His focus area is vascular disease and inflammation as well as stem cell therapy. He joined Dupage Medical Technology, Inc in June, 2023.including the Technology Transfer Awards (1989 and 1994) from the International Union Against Cancer (UICC), Geneva, the First Award from the National Institutes of Health (1997); ARA Award from Parke-Davis/Pfizer Foundation (2000); and the Fourjay Foundation Cardiovascular Research Award (2001). Dr. Geng is an internationally recognized expert in stem cell research, and is a member of numerous research review committees, including those of the American Heart Association and the National Institutes of Health. He served on the editorial boards of many scientific journals, such as Circulation and Circulation Research, two top journals of the American Heart Association. He is also members of editorial boards of other professional journals, such as Vascular Pharmacology, and World Journal of Stem Cells. He served as a keynote or invited speaker and presenter in many professional conferences and different universities worldwide. As a very productive physician-scientist Dr. Geng has published many scientific articles, book chapters and reviews. Thus far, his Google Scholar profile has had 16306 citations and h-index 62. Dr. Geng is a founder of several biotech startups and inventor of more than 20 US and international patents, awarded or pending. His focus area is vascular disease and inflammation as well as stem cell therapy.